GOALS: The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy. MATERIALS AND METHODS: Patients with advanced CRC having one prior chemotherapy regimen received 480 ml of EPA-ONS daily for 3 weeks before commencing chemotherapy with folinic acid, 5-fluorouracil, irinotecan (FOLFIRI), and continued for 3 cycles of treatment (9 weeks). All assessments including weight, body composition, C-reactive protein (CRP), QOL, dietary intake, PPL and cytokine analyses were performed at baseline, 3 and 9 weeks. RESULTS: Twenty-three patients were enrolled, 20 completed 3 weeks, and 15 completed 9 weeks. The mean EPA-ONS intake was 1.7 tetrapaks (408 ml) daily. There was a significant increase in mean weight (2.5 kg) at 3 weeks (p=0.03). Lean body mass (LBM) was maintained. Protein and energy intake significantly decreased after the commencement of chemotherapy (protein p=0.003, energy p=0.02). There was a significant increase in energy levels (p=0.03), whilst all other QOL measures were maintained. PPL EPA levels increased significantly over the first 3 weeks. Mean CRP increased by 14.9 mg/L over the first 3 weeks (p=0.004), but decreased to baseline levels by the end of the trial. There was a significant correlation between plasma IL-6 and IL-10 concentrations and survival, and between IL-12 and toxicity. CONCLUSION: Dietary counseling and the provision of EPA-ONS may result in maintenance of nutritional status and QOL, however randomized trials are required to evaluate the impact of EPA on toxicity from chemotherapy.
GOALS: The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy. MATERIALS AND METHODS:Patients with advanced CRC having one prior chemotherapy regimen received 480 ml of EPA-ONS daily for 3 weeks before commencing chemotherapy with folinic acid, 5-fluorouracil, irinotecan (FOLFIRI), and continued for 3 cycles of treatment (9 weeks). All assessments including weight, body composition, C-reactive protein (CRP), QOL, dietary intake, PPL and cytokine analyses were performed at baseline, 3 and 9 weeks. RESULTS: Twenty-three patients were enrolled, 20 completed 3 weeks, and 15 completed 9 weeks. The mean EPA-ONS intake was 1.7 tetrapaks (408 ml) daily. There was a significant increase in mean weight (2.5 kg) at 3 weeks (p=0.03). Lean body mass (LBM) was maintained. Protein and energy intake significantly decreased after the commencement of chemotherapy (protein p=0.003, energy p=0.02). There was a significant increase in energy levels (p=0.03), whilst all other QOL measures were maintained. PPL EPA levels increased significantly over the first 3 weeks. Mean CRP increased by 14.9 mg/L over the first 3 weeks (p=0.004), but decreased to baseline levels by the end of the trial. There was a significant correlation between plasma IL-6 and IL-10 concentrations and survival, and between IL-12 and toxicity. CONCLUSION: Dietary counseling and the provision of EPA-ONS may result in maintenance of nutritional status and QOL, however randomized trials are required to evaluate the impact of EPA on toxicity from chemotherapy.
Authors: M Elia; M A E Van Bokhorst-de van der Schueren; J Garvey; A Goedhart; K Lundholm; G Nitenberg; R J Stratton Journal: Int J Oncol Date: 2006-01 Impact factor: 5.650
Authors: D W Nixon; M Kutner; S Heymsfield; A T Foltz; C Carty; S Seitz; K Casper; W K Evans; K N Jeejeebhoy; J M Daly Journal: Metabolism Date: 1988-11 Impact factor: 8.694
Authors: J E M Crozier; R F McKee; C S McArdle; W J Angerson; J H Anderson; P G Horgan; D C McMillan Journal: Br J Cancer Date: 2006-05-23 Impact factor: 7.640
Authors: Aja S McCutchen; Juan Carlos Munoz; Lacie Brenner; Peter Wludyka; Kenneth J Vega Journal: Int J Colorectal Dis Date: 2011-01-27 Impact factor: 2.571
Authors: Honor A Blackwood; Charlie C Hall; Trude R Balstad; Tora S Solheim; Marie Fallon; Erna Haraldsdottir; Barry J Laird Journal: Support Care Cancer Date: 2019-07-29 Impact factor: 3.603
Authors: Michel Carlos Mocellin; Juliana de Aguiar Pastore e Silva; Carolina de Quadros Camargo; Maria Emília de Souza Fabre; Scheila Gevaerd; Katya Naliwaiko; Yara Maria Franco Moreno; Everson Araújo Nunes; Erasmo Benicio Santos de Moraes Trindade Journal: Lipids Date: 2013-07-26 Impact factor: 1.880
Authors: Sally Wheelwright; Anne-Sophie Darlington; Jane B Hopkinson; Deborah Fitzsimmons; Alice White; Colin D Johnson Journal: Support Care Cancer Date: 2013-06-25 Impact factor: 3.603